This clinical trial is for participants with relapsed/refractory follicular lymphoma.

The purpose of this study is to understand more about whether the investigational drug, tazemetostat, in combination with lenalidomide and rituximab will be a useful treatment for people with relapsed/refractory follicular lymphoma. An investigational drug means that it has not yet been approved by the United States Food and Drug Administration (FDA).

This study is for men and women who have undergone surgery for a neurological condition, including brain tumors, vascular disorders such as aneurysms or arteriovenous malformations, or elective surgery for epilepsy or Chiari malformation.
   

This clinical trial is for adult participants who have breast cancer that is advanced or that has spread to other parts of the body.
   
The purpose of this study is to evaluate the safety and effectiveness of a new drug called gedatolisib when combined with other cancer drugs, compared to the standard of care. The standard of care is a drug or drug combination that is usually given to patients with breast cancer. Gedatolisib, which is intended to slow or stop the growth of cancer, is not yet approved by the United States Food and Drug Administration (FDA).

This study is for men and women who have been diagnosed with cancer of unknown primary (CUP) origin.
   
The purpose of this study is to understand specific changes in the genes of patients with cancers of unknown primary, a relatively common disease that accounts for about 3–9% of all cancer diagnoses. In the USA alone, this occurs in more than 80,000 patients every year.

This study is for men and women recently diagnosed with and/or under treatment for cancer at Weill Cornell Medicine/NewYork-Presbyterian Hospital.
   

The purpose of this study is to test a new experimental drug called SAR443579 for the treatment of participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), and high risk-myelodysplasia (HR-MDS).

Experimental means that it has not been approved by the US Food and Drug Administration (FDA) to be prescribed to patients.

This clinical trial is for men and women with a diagnosis of chronic lymphocytic leukemia (CLL) and Richter’s transformation. Richter’s transformation occurs when CLL changes into a type of diffuse large B cell lymphoma (DLBCL).
   
The purpose of this study is to evaluate the safety and efficacy of the investigational drug, Polatuzumab vedotinin, in combination with a standard chemoimmunotherapy regimen.

This clinical trial is for non-gender specific adults ages 18-100 years old with H.pylori infection.
   
The purpose of this study is to learn how the H.pylori infection can lead to cancer as well as provide information on possible intervention treatments that can be administered prior to the development of advanced cancer.
   

 This clinical trial is for participants with diffuse midline glioma (DMG). 

This is an observational study for people with myelofibrosis (MF), lower risk or higher risk myelodysplastic syndromes (MDS), Idiopathic Cytopenia of Undetermined Significance (ICUS), and acute myeloid leukemia (AML).